Skip to main content
$1.07 -$0.01 (-0.9%)

04:00 PM EST on 12/05/23

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

CAPS Rating: No stars

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.

Current Price $1.07 Mkt Cap $186.6M
Open $1.08 P/E Ratio -7.62
Prev. Close $1.07 Div. (Yield) $0.00 (0.0%)
Daily Range $1.07 - $1.11 Volume 516,318
52-Wk Range $0.71 - $2.04 Avg. Daily Vol. 1,162,503

Caps

How do you think NASDAQ:RIGL will perform against the market?

Add Stock to CAPS Watchlist

All Players

148 Outperform
58 Underperform
 

All-Star Players

23 Outperform
15 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:RIGL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Momentum21 (34.26)
Submitted April 05, 2013

Obviously this puts them in a tough spot with Fostamatinib but they do have a few bullets left to fire in 2013 along with some cash that was raised at the end of 2012. I think the offering priced at 9.50. Not saying I have much of a valuation model… More

ScreenerStizBear (51.33)
Submitted June 26, 2008

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Fools bullish on NASDAQ:RIGL are also bullish on:

Fools bearish on NASDAQ:RIGL are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about RIGL.

Recs

0
Member Avatar emtking (49.00) Submitted: 12/28/2022 2:04:51 PM : Outperform Start Price: $1.27 NASDAQ:RIGL Score: +78.32

FDA approval of a new cancer drug MONTHS ahead of schedule. This is the first time in my life I have heard of this. It went on sale in Q4 of 2022, at a price of something crazy like $33,000 per year. They just started another drug trial. I think this makes them a takeover target. They were at risk of delisting when the FDA approval announcement came out. They were around $0.63 per share then, and were being piled on by shorts. They made the 10+ days in a row above $1 per share, and now trade about 100% above that 52 week low. Although still on shaky ground in the worst stock market in 14 years, RIGL looks to be making a strong base above $1/sh and headed higher in 2023. Adding shares in Roth, Traditional IRA, and Calls in non qualified account. 1 year average analyst price target is above $3/share.

Recs

0
Member Avatar Bigsef77 (48.50) Submitted: 7/14/2020 5:45:53 PM : Outperform Start Price: $2.56 NASDAQ:RIGL Score: -150.23

COVID trials

Recs

0
Member Avatar raspoutine (< 20) Submitted: 6/4/2019 3:41:48 PM : Outperform Start Price: $2.14 NASDAQ:RIGL Score: -112.28

indication for their approved drug.

Leaderboard

Find the members with the highest scoring picks in RIGL.

Score Leader

qubit15

qubit15 (26.44) Score: +555.10

The Score Leader is the player with the highest score across all their picks in RIGL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
qubit15 26.44 1/21/2009 Underperform NS $6.95 -84.60% +470.50% +555.10 0 Comment
robo2011 21.60 11/17/2008 Underperform NS $6.53 -83.61% +442.30% +525.91 0 Comment
anticitradeshort 28.14 4/20/2009 Underperform NS $6.43 -83.36% +439.34% +522.70 0 Comment
cybob2000 52.12 10/23/2008 Underperform 3W $15.64 -93.16% +418.83% +511.99 0 Comment
schwah8 97.80 10/13/2008 Underperform NS $18.26 -94.14% +395.85% +489.99 0 Comment
EV38biotech < 20 11/5/2008 Underperform 5Y $8.60 -87.56% +376.05% +463.61 0 Comment
Mynx828 64.54 9/17/2009 Underperform 5Y $7.45 -85.64% +328.09% +413.73 0 Comment
longtermgrowth09 60.55 12/17/2009 Underperform 5Y $8.97 -88.07% +312.39% +400.46 0 Comment
darksider389 84.22 7/7/2008 Underperform 3M $21.97 -95.13% +278.41% +373.54 0 Comment
flats66 65.20 8/14/2008 9/18/2009 Underperform 3Y $22.71 -95.29% +268.43% +363.72 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for RIGL.